Premium
Benzodiazepine Use in Older Adults in the United States, Ontario, and Australia from 2010 to 2016
Author(s) -
Brett Jonathan,
Maust Donovan T.,
Bouck Zach,
Ignacio Rosalinda V.,
Mecredy Graham,
Kerr Eve A.,
Bhatia Sacha,
Elshaug Adam G.,
Pearson Sallie A.
Publication year - 2018
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/jgs.15292
Subject(s) - medicine , incidence (geometry) , demography , population , cohort study , observational study , cohort , gerontology , environmental health , physics , sociology , optics
OBJECTIVES To detail annual trends in benzodiazepine incidence and prevalence in older adults between 2010 and 2016 in three countries. Design Observational multicountry cohort study with harmonized study protocol. Setting The United States (veteran population); Ontario, Canada; and Australia. Participants All people aged 65 and older (8,270,000 people). Measurements Annual incidence and prevalence of benzodiazepine use stratified according to age group (65–74, 75–84, ≥85) and sex. We performed multiple regression analyses to assess whether rates of incident and prevalent use changed significantly over time. Results Over the study period, we observed a significant decrease in incident benzodiazepine use in the United States (2.6% to 1.7%) and Ontario (6.0% to 4.4%) but not Australia (7.0% to 6.7%). We found significant declines in prevalent use in all countries (United States: 9.2% to 7.3%; Ontario: 18.2% to 13.4%; Australia: 20.2% to 16.8%). Although incidence and prevalence increased with age in Ontario and Australia, they decreased with age in the United States. Incidence and prevalence were higher in women in all countries. Conclusion Consistent with other international studies, there have been small but significant reductions in the incidence and prevalence of benzodiazepine use in older adults in all three countries, with the exception of incidence in Australia, although use remains inappropriately high—particularly in those aged 85 and older—which warrants further attention from clinicians and policy‐makers.